Highlights mirtazapine's efficacy for nausea in Parkinson’s disease, suggesting new treatment options.
To highlight the potential role of off-label mirtazapine in treating refractory gastroparesis-related nausea in Parkinson’s disease (PD), thereby expanding current approaches to non-motor symptom management and contributing to the growing literature on therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Orozco et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: